Biomarker detection method 'could improve cancer treatment'
Date posted: 30 Jun 2009
A new biomarker method developed by scientists could be used to increase the number of diagnostic tests for cancer.
The new method, developed by researchers at the National Cancer Institute (NCI) could increase the accuracy of detecting real cancer biomarkers that will help to detect cancer in its earliest stages.
Researchers hope that the new technology will be used to detect the strongest biomarker candidates, because the method, using protein markers in bodily fluids, makes it possible to screen hundreds of patient samples at a time.
A new biomarker method developed by scientists could be used to increase the number of diagnostic tests for cancer.
The new method, developed by researchers at the National Cancer Institute (NCI) could increase the accuracy of detecting real cancer biomarkers that will help to detect cancer in its earliest stages.
Researchers hope that the new technology will be used to detect the strongest biomarker candidates, because the method, using protein markers in bodily fluids, makes it possible to screen hundreds of patient samples at a time.
NCI director John Niederhuber explained that the findings are significant because they potentially eliminate a major hurdle to validating biomarkers for clinical use.
He said: "Thousands of cancer biomarkers are discovered every day, but only a handful ever makes it through clinical validation.
"This is a critical roadblock because biomarkers have the potential to allow doctors to detect cancer in the earliest stages, when treatment provides the greatest chances of survival."
It follows recent research by Cancer Research, published in the American Association for Cancer Research journal, which highlighted a new biomarker that could be used to detect brain tumours.
Click here to email or call on 01223 225181.
Partner
Our team work with a range of technology clients from early stage through to major deals such as the $500m collaboration and licensing deal between Argenta Discovery and AstraZeneca.
Learn more...
